Moleculin Biotech Inc. (MBRX)
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
Vicarious Surgical Inc. - Vicarious Surgical Advances Toward Design Freeze with Successful In-Vivo Porcine Lab
Schrödinger, Inc. - Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Allurion - Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
Mirum Pharma - Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum